Related references
Note: Only part of the references are listed.Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA
Benedikt Feuerecker et al.
EUROPEAN UROLOGY (2021)
Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study
Andrei Gafita et al.
LANCET ONCOLOGY (2021)
Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake
Rudolf A. Werner et al.
MOLECULAR IMAGING AND BIOLOGY (2020)
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer
John Violet et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Quantitative Test-Retest Measurement of 68Ga-PSMA-HBED-CC in Tumor and Normal Tissue
Janet H. Pollard et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
Michael S. Hofman et al.
LANCET (2020)
Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study
Andrei Gafita et al.
EUROPEAN UROLOGY (2020)
Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial
Bastiaan M. Prive et al.
BMC CANCER (2020)
Day-to-day variability of [68Ga]Ga-PSMA-11 accumulation in primary prostate cancer: effects on tracer uptake and visual interpretation
Judith Olde Heuvel et al.
EJNMMI RESEARCH (2020)
Results of a Prospective Phase 2 Pilot Trial of 177Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression
Louise Emmett et al.
CLINICAL GENITOURINARY CANCER (2019)
qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using 68Ga-PSMA11 PET/CT
Andrei Gafita et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial
Wolfgang P. Fendler et al.
JAMA ONCOLOGY (2019)
Pretherapeutic 68Ga-PSMA-617 PET May Indicate the Dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in Main Organs and Tumor Lesions
Jingnan Wang et al.
CLINICAL NUCLEAR MEDICINE (2019)
Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
John Violet et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Healthy Tissue Uptake of 68Ga-Prostate-Specific Membrane Antigen, 18F-DCFPyL, 18F-Fluoromethylcholine, and 18F-Dihydrotestosterone
Bernard H. E. Jansen et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Evaluation of SUV normalized by lean body mass (SUL) in 68Ga-PSMA11 PET/CT: a bi-centric analysis
Andrei Gafita et al.
EJNMMI RESEARCH (2019)
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Michael S. Hofman et al.
LANCET ONCOLOGY (2018)
Effects of Tumor Burden on Reference Tissue Standardized Uptake for PET Imaging: Modification of PERCIST Criteria
Benjamin L. Viglianti et al.
RADIOLOGY (2018)
Radiation Dosimetry for 177Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions
Shozo Okamoto et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0
Wolfgang P. Fendler et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer
Florian C. Gaertner et al.
ONCOTARGET (2017)
Biodistribution and radiation dosimetry of 68Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer
Christian H. Pfob et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
Peptide receptor radionuclide therapy for neuroendocrine tumours: standardized and randomized, or personalized?
Michael S. Hofman et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy
Jean-Mathieu Beauregard et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2012)
Radionuclide bone imaging: An illustrative review
C Love et al.
RADIOGRAPHICS (2003)
Share Paper
